Once-weekly subcutaneous injection of semaglutide for type 2 diabetes; lowers blood sugar and supports weight loss by mimicking GLP-1 hormone to slow gastric emptying and increase insulin secretion.
Weekly dulaglutide injection for type 2 diabetes; GLP-1 receptor agonist that improves glycemic control, reduces cardiovascular risk, and promotes modest weight loss.
Daily single-tablet regimen combining bictegrivir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment in adults and children; suppresses viral load with high barrier to resistance.
Twice-daily sacubitril/valsartan tablets for heart failure with reduced ejection fraction; reduces hospitalization risk by inhibiting neprilysin and blocking angiotensin II receptors.
Biweekly adalimumab injections for rheumatoid arthritis, psoriasis, and Crohn's; TNF-alpha blocker that reduces inflammation and joint damage.
Weekly etanercept injections for rheumatoid arthritis and psoriasis; TNF inhibitor that modulates immune response to prevent disease flares.
Daily dolutegravir tablets as part of HIV regimen; integrase strand transfer inhibitor that prevents viral DNA integration into host cells.
Once-daily ledipasvir/sofosbuvir tablets for 8-12 weeks to cure chronic hepatitis C genotype 1; NS5A and polymerase inhibitors for high cure rates.